Evidence map›Paper›PMID 27308555›Full record

ArticleMolecular & cellular oncology2016

The stress of coping with E2F loss.

Ainhoa Iglesias-Ara, Ana M Zubiaga

Abstract read
In one paragraph

Article in Molecular & cellular oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Golgi OncoproteinGenes · 2019
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Ainhoa Iglesias-AraDepartment of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country, UPV/EHU , Bilbao, Spain.
Ana M ZubiagaDepartment of Genetics, Physical Anthropology and Animal Physiology, University of the Basque Country, UPV/EHU , Bilbao, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

E2F transcription factors are key regulators of cellular proliferation, and altered E2F activity is a common feature of tumor cells. Thus, E2F targeting is being explored as a therapeutic strategy in cancer. Importantly, recent mouse knockout studies show that concomitant loss of E2f1/E2f2 activity is associated with increased genomic instability and oncogenic potential in normal differentiating cells, a finding that might have implications for cancer therapy.

Indexed as

ApoptosisDNA damage responseE2p53replication stresssenescence

Identifiers

PMID27308555
PMCPMC4845195

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.